Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2171 vs placebo in metastatic or recurrent renal cell carcinoma
2006-002455-33Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in renal cell carcinoma (RCC) comparing AZD2171 45 mg with Placebo (2 arms). Primary endpoints: Change in tumor size at 12 weeks and RECIST-based efficacy assessment. Started Aug 2006; status: completed.
02
Drugs
cediranib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2006-002455-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002455-33.